India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement

Rishika Sadam

Mon, Jul 14, 2025, 7:38 PM 1 min read

By Rishika Sadam

(Reuters) -India's apical drugmaker by gross Sun Pharma connected Monday launched its anti-baldness cause Leqselvi successful the U.S., pursuing the colony of a patent quality with Incyte Corp.

The institution said 8 mg Leqselvi tablets for terrible alopecia areata volition beryllium disposable successful the U.S., aft a motorboat hold caused by a patent infringement lawsuit successful a U.S. court.

Shrikant Akolkar, expert astatine Nuvama Institutional Equities, said the cause could make up to $400 cardinal successful income by FY30, with highest income imaginable of $900 million, and boost maturation successful Sun's cardinal U.S. market.

"This colony is precise affirmative and determination is nary overhang of immoderate ineligible quality anymore. The cause has precise bully objective information and with this launch, Sun Pharma's commercialized portfolio broadens further," helium said.

India's drugmakers person been grappling with pricing unit and stiff contention successful the U.S.

The institution said the drug's summation to its dermatology portfolio is simply a "key milestone", arsenic it focuses connected caller therapy areas.

Alopecia areata is an autoimmune illness that causes patchy hairsbreadth nonaccomplishment connected the scalp and different areas of the body.

(Reporting by Rishika Sadam and Manvi Pant; Editing by Mrigank Dhaniwala and Vijay Kishore)